JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Slides:

Advertisements

Similar presentations

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

Advertisements

THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA Coordinator: Asist. Univ. Dr. Marcela Candea Authors: Ioana-Violeta Oltean Ioana Barsan Madalina.

Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon -2a (peg-IFN-2a) Therapy.

Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.

THROMBOSIS RISK IN ESSENTIAL THROMBOCYTOSIS CORRELATES WITH HEMOGLOBIN VALUES Study group for acute leukemias and myeloproliferative neoplasms Greek Society.

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

CCO Independent Conference Highlights

PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation by Vittorio Rosti, Laura Villani, Roberta Riboni, Valentina Poletto,

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Hydroxyurea makes inflammation “just right”?

by Henrik Frederiksen, and Kai Schmidt

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Chronic Myeloproliferative Neoplasms (MPN) Ph-negative

Finding a diamond in the (mouse is) rough

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance by Elisabetta Antonioli, Paola Guglielmelli,

In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew.

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome by Fiorina.

Ayalew Tefferi, MD, Tiziano Barbui, MD Mayo Clinic Proceedings

Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia Fabrice Usseglio, Nathalie Beaufils, Anne Calleja, Sophie.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

ROCK and Rho(ll) in bone marrow

Blocking VWF platelet binding to treat TTP

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Has MRD monitoring superseded other prognostic factors in adult ALL?

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors by Teal S. Hallstrand,

A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,

Ayalew Tefferi, Pierre Noel, Curtis A. Hanson

by Geling Li, Emily Waite, and Julie Wolfson

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms Janine Prick, Gerald de Haan, Anthony R. Green,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum Experimental Hematology

Overcoming “aspirin resistance” in MPN

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy by Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica.

Rituximab immunotherapy: it’s getting personal

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

How I treat heparin-induced thrombocytopenia and thrombosis

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Myeloproliferative neoplasms and thrombosis

Initial treatment of CLL: integrating biology and functional status

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

How I treat essential thrombocythemia

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Cold agglutinin disease

Presentation transcript:

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients by Marina Panova-Noeva, Marina Marchetti, Sabrina Buoro, Laura Russo, Annamaria Leuzzi, Guido Finazzi, Alessandro Rambaldi, Cosimo Ottomano, Hugo ten Cate, and Anna Falanga Blood Volume 118(9):2599-2601 September 1, 2011 ©2011 by American Society of Hematology

IPF parameters according to JAK2V617F mutation and therapy. IPF parameters according to JAK2V617F mutation and therapy. Panels are showing: (A) platelet count, (B) IPF count, (C) percentage of IPF, and (D) percentage of H-IPF. Data are mean ± SD. CTR indicates controls; JAK2+, JAK2V617F-positive patients; JAK2−, JAK2V617F-negative patients. *P < .05 vs CTR. §P < .05 vs HU JAK2+. £P < .05 vs HU JAK2+, HU JAK2−. &P < .05 vs non-HU JAK2−, HU JAK2−, HU JAK2+. **P < .05 vs non-HU JAK2−. Marina Panova-Noeva et al. Blood 2011;118:2599-2601 ©2011 by American Society of Hematology